

Resignation of Director

Milan (Italy), 4 November 2011 - MolMed S.p.A. (Milan:MLM) announces that Renato Botti today communicated to the Company his resignation from the position of non-independent and non-executive member of MolMed's Board of Directors, with immediate effect. The decision is motivated by the termination of his fiduciary relationship with *Fondazione San Raffaele*, the reference shareholder of MolMed's shareholder Science Park Raf. Renato Botti held no other position within MolMed and holds no shares of the Company.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14.5.1999 as subsequently amended.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes two novel therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent (VTA), in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The company's shares are listed on the Milan Stock Exchange, at the Standard segment (class I) of the MTA managed by *Borsa Italiana*.

For further information, please contact:

Investor Relations:

Holger Neecke
Director Business Development & Investor Relations
MolMed S.p.A.
phone: +39 02 21277.205
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

Administration, Finance & Control:

Enrico Cappelli
Chief Financial Officer
MolMed S.p.A.
phone: +39 02 21277.302
fax: +39 02 21277.325
e-mail: enrico.cappelli@molmed.com

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.